Kovack Advisors’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-3,280
Closed -$344K – 612
2024
Q3
$344K Buy
3,280
+350
+12% +$40.9K 0.04% 408
2024
Q2
$417K Buy
2,930
+895
+44% +$103K 0.05% 343
2024
Q1
$227K Sell
2,035
-100
-5% -$11.9K 0.03% 412
2023
Q4
$277K Buy
2,135
+64
+3% +$8.82K 0.03% 438
2023
Q3
$338K Buy
2,071
+291
+16% +$51.2K 0.05% 357
2023
Q2
$326K Buy
1,780
+150
+9% +$21.6K 0.04% 400
2023
Q1
$217K Buy
+1,630
New +$192K 0.03% 496

Other funds holding ACLS

Kovack Advisors's ACLS Position: Q4 2024 in Review

Kovack Advisors sold out of Axcelis (ACLS) in Q4 2024, closing a stake of 3,280 shares — an estimated $344K sold.

Kovack Advisors first reported a position in ACLS in Q1 2023 and held it in 7 quarters. The position peaked at $417K in Q2 2024. 325 funds tracked by Wall St. Rank hold ACLS as of Q4 2024.

  • Kovack Advisors reported no remaining Axcelis position as of Q4 2024 after selling out during the quarter.
  • Kovack Advisors sold 3,280 Axcelis shares in Q4 2024, an estimated $344K.
  • Kovack Advisors first reported a position in Axcelis in Q1 2023 and held it in 7 quarters.
  • Kovack Advisors's Axcelis position peaked at $417K in Q2 2024.
  • 325 funds tracked by Wall St. Rank held Axcelis as of Q4 2024.

Based on Kovack Advisors's 13F filing for Q4 2024, filed 5 Feb 2025.